Endometrioid ovarian carcinoma benefts from aromatase inhibitors: Case report and literature review

Current Oncology

Volumn 17, Issue 6, 2010, Pages 82-85

  Pan, Y ^a   Kao, M S ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aromatase inhibitor; Endometrioid ovarian cancer; Letro zole; Maintenance therapy; Recurrent ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; LETROZOLE; PACLITAXEL; PROGESTERONE RECEPTOR;

ADULT; CANCER GRADING; CANCER REGRESSION; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; ENDOMETRIOID OVARY CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LAPAROTOMY; LIVER TUMOR; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PELVIS TUMOR; QUALITY OF LIFE; REVIEW; SECOND LOOK SURGERY; SPLENECTOMY; TUMOR BIOPSY;

EID: 78650154308     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Makar AP. Hormone therapy in epithelial ovarian cancer. En-docr Relat Cancer 2000;7:85-93.
2. Hamerlynck JV, Maskens TH, Mangioni C, et al. Phase ii trial of medroxyprogesterone acetate in advanced ovarian cancer: an eortc Gynecological Cancer Cooperative Group Study. Gynecol Oncol 1985;2:313-316.
3. Bowman A, Gabra H, Langdon SP, et al. CA125 response is associated with estrogen receptor expression in a phase ii trial of letrozole in ovarian cancer: identifcation of an endocrine sensitive subgroup. Clin Cancer Res 2002;8:2233-2239.
4. del Carmen MG, Fuller AF, Matulonis U, et al. Phase ii trial of anastrozole in women with asymptomatic Müllerian cancer. Gynecol Oncol 2003;91:596-602.
5. Papadimitriou CA, Markaki S, Siapkaras J, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase ii study. Oncology 2004;66:112-117.
6. Smyth JF, Gourley C, Walker G, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letro-zole in estrogen-receptor positive patients. Clin Cancer Res 2007;13:3617-22.
7. Ramirez PT, Schmeler KM, Milam MR, et al. Effcacy of letro-zole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol 2008;110:56-59.
8. Risch HA. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 1996;63:254-257.
9. Weiss NS, Lyon JL, Krishnamurthy S, Dietert SE, Liff JM, Daling JR. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 1982;68:95-98.
10. Kuhnel R, Delemarre JF, Rao BR, Stolk JG. Correlation of aromatase activity and steroid receptors in human ovarian carcinoma. Anticancer Res 1986;6:889-892.
11. Cohen I. Endometrial pathologies associated with postmeno-pausal tamoxifen treatment. Gynecol Oncol 2004;94:256-266.
12. Salazar EL, Paredes A, Calzada L. Endometrial thickness of postmenopausal breast cancer patients treated with tamoxifen. Gynecol Endo 2005;21:312-316.
13. Garuti G, Cellani F, Centinaio G, Montanari G, Nalli G, Luerti M. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitor. Gynecol Oncol 2006;103:599-603.
14. Bertelli G, Hall E, Ireland E, et al. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (ie s)-a randomized cont rolled trial of exemest ane versus continued ta-moxifen after 2-3 years tamoxifen. Ann Oncol 2010;21:498-505.
15. Brodie A, Sabnis G, Macedo L. Xenograft models for aromatase inhibitor studies. J Steroid Biochem Mol Biol 2007;106:119-124